

INTRODUCTION

The 5-year overall survival of patients diagnosed with SCLC is <10% [1].

Characterizing patients who achieve prolonged survival may inform prognostic stratification and therapeutic decision-making.

METHODS

Design:

We conducted a retrospective descriptive study at the oncology department of Abderrahmen Mami Hospital between 2020 and 2024.

Long-term survivors were defined by a survival threshold of ≥ 24 months [2].

Clinical, therapeutic, and outcome data were collected and analyzed.

DISCUSSION AND CONCLUSION

Actionable Take Away Message

- Identify favorable candidates
- Treat early
- Use a multimodal strategy
- Individualize treatment decisions

Future Direction for Research

- Development of predictive tools to identify patients most likely to benefit from intensified multimodal and sequential treatment strategies, ultimately supporting more personalized care.

REFERENCES & ACKNOWLEDGEMENTS

1. Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839-853.
2. Gobbini E, Diallo MH, Pasquier D, et al. Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 2025;202:108499. doi:10.1016/j.lungcan.2025.108499.

We sincerely thank the patients and their families for their contribution to this study. We also acknowledge the medical, nursing, and supportive care teams of the Oncology Department of Abderrahmen Mami Hospital for their dedication to patient care and their contribution to this work.



**All authors responsible for content disclose that AI was NOT used in the development of the material .*

RESULTS

- 7 long term survivors out of 114 patients diagnosed with SCLC
- All patients were male ♂
- All patients had ECOG PS = 0-1
- Median age : 61
- Median smoking exposure : 54 pack year 
- 5 patients received second-line chemotherapy
- 4 patients received third-line treatment
- Median follow-up 27 months

Table 1 : First-line treatment

1st line systemic chemotherapy	N
Etoposide cisplatin	2
Etoposide carboplatin	3
Irinotecan carboplatin	2

Progressive Disease

Stable Disease

Partial Response

Complete Response




Figure 1 : Disease Characteristics




Figure 2 : Response to First-line treatment




Figure 3 : Patient Clinical Status at last follow-up